Stockscreener 앱 받기
1.99
1.00%
-0.02
시간 외 거래:
2.02
0.03
+1.51%
Immutep Limited Adr 주식(IMMP)의 최신 뉴스
Immutep Announces Successful Completion of FDA Project Optimus Requirements - The Manila Times
Is Immutep Limited Depositary Receipt stock ready for a breakoutPortfolio Value Summary & Daily Volume Surge Signals - newser.com
Reversal indicators forming on Immutep Limited Depositary Receipt stockMarket Activity Summary & Safe Entry Point Alerts - newser.com
What momentum shifts mean for Immutep Limited Depositary Receipt2025 Bull vs Bear & AI Forecasted Stock Moves - newser.com
Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025 - GlobeNewswire Inc.
Immutep Limited Depositary Receipt Stock Lags Behind Sector BenchmarksMarket Performance Report & Weekly Setup with High ROI Potential - beatles.ru
Immutep Limited (IMMP) Receives Positive FDA Feedback on Future Clinical Development of Eftilagimod Alfa - Yahoo Finance
12 Best Australian Stocks to Buy Right Now - Insider Monkey
Immutep Gains FDA Support for Cancer Therapy Development - TipRanks
Is Immutep Limited Depositary Receipt a good long term investmentFree Stock Market Return Analysis - PrintWeekIndia
Immutep Limited Depositary Receipt Stock Analysis and ForecastExceptional gains - jammulinksnews.com
Millennium Management LLC Sells 19,242 Shares of Immutep Limited (NASDAQ:IMMP) - Defense World
Jane Street Group LLC Has $98,000 Position in Immutep Limited (NASDAQ:IMMP) - Defense World
Immutep Ltd Highlights Immune System Innovations at Healthcare Conference - TipRanks
Market Highlights: Immutep Limited ADR (IMMP) Ends on a Low Note at 1.93 - DWinneX
Immutep stock soars on promising trial results By Investing.com - Investing.com Australia
Immutep stock soars on promising trial results - Investing.com
Immutep Quarterly Activities Report Q3 FY25 - The Manila Times
Immutep Advances Cancer Trials with Promising Developments - TipRanks
Is Immutep Limited (IMMP) the Best Long Term ASX Stock to Buy Now? - AInvest
Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761 - GlobeNewswire
Baird cuts Immutep stock target on phase 2b trial results, retains Outperform - Investing.com
Immutep appoints research institute to conduct first-in-human study of IMP761 - Biotech Dispatch
Immutep LimitedADR (IMMP) Price Target Increased by 5.10% to 2.59 - Nasdaq
Immutep Announces Successful Meeting with the FDA on - GlobeNewswire
ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index - FinancialContent
FDA Grants Fast Track Designation to 1L Eftilagimod Alpha for Recurrent or Metastatic HNSCC - targetedonc.com
72 Biggest Movers From Friday - Benzinga
IMMPImmutep Latest Stock News & Market Updates - Stock Titan
Immutep Ltd (IMMP) Stock Price, Trades & News - GuruFocus
Immutep valuation increased 16% to $510 million by Edison Investment Research - Proactive financial news
A Full List of Australia ADRs - Investing.com Australia
Prima BioMed (IMMP) Stock Price, News & Analysis - MarketBeat
Prima BioMed Share Price | NASDAQ IMMP Stock - Investing.com Australia
Prima BioMed Stock Price Today | NASDAQ: IMMP Live - Investing.com
Prima BioMed Stock Price Today | NASDAQ IMMP - Investing.com Canada
Immutep Ltd Share Price | ASX IMM Stock - Investing.com Australia
ADVFN | Live Stock, Options & Crypto Market Data, Trading Tools & Community - advfn.com
1.11%
자본화:
|
볼륨(24시간):